Author:
Obata Honoka,Minegishi Katsuyuki,Nagatsu Kotaro,Ogawa Mikako,Zhang Ming-Rong
Abstract
AbstractWe developed a novel method for production of no-carrier-added (n.c.a.) [188, 189, 191Pt]PtIICl42− from an Ir target material, and then synthesized n.c.a. [*Pt]cis-[PtIICl2(NH3)2] ([*Pt]cisplatin) from [*Pt]PtIICl42−. [*Pt]PtIICl42− was prepared as a synthetic precursor of n.c.a. *Pt complex by a combination of resin extraction and anion-exchange chromatography after the selective reduction of IrIVCl62− with ascorbic acid. The ligand-substitution reaction of Cl with NH3 was promoted by treating n.c.a. [*Pt]PtIICl42− with excess NH3 and heating the reaction mixture, and n.c.a. [*Pt]cisplatin was successfully produced without employing precipitation routes. After this treatment, [*Pt]cisplatin was isolated through preparative HPLC with a radiochemical purity of 99 + % at the end of synthesis (EOS).
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Kratochwil, C. et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941–1944 (2016).
2. Filosofov, D., Kurakina, E. & Radchenko, V. Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations. Nucl. Med. Biol. 94–95, 1–19 (2021).
3. Rebischung, C. et al. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX Plus 125IUdR. Int. J. Radiat. Biol. 84(12), 1123–1129 (2008).
4. Vallis, K. A. et al. Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of 111In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. Am. J. Nucl. Med. Mol. Imaging 4(2), 181–192 (2014).
5. Jong, M. et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med. 32(2), 133–140 (2002).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献